Single-dose smallpox vaccine could be effective against mpox

In a recent study posted to medRxiv* preprint server, researchers estimated the efficacy of a single-dose Modified Vaccinia Ankara-Bavaria Nordic (MVA-BN) vaccine against mpox (MPX) in gay, bisexual, and other men who have sex with men (GBMSM).

Study: Effectiveness of one dose of MVA-BN smallpox vaccine against monkeypox in England using the case-coverage method. Image Credit: Dotted Yeti/Shutterstock
Study: Effectiveness of one dose of MVA-BN smallpox vaccine against monkeypox in England using the case-coverage method. Image Credit: Dotted Yeti/Shutterstock

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

The World Health Organization declared the ongoing MPX outbreak a public health emergency of international concern in July 2022. The European Union/European Economic Area (EU/EEA) recorded over 20,000 cases until October 11, 2022. Vaccination using a third-generation smallpox vaccine has been a pivotal component of MPX control. MVA-BN is one such replication-deficient attenuated smallpox vaccine.

It was approved for smallpox and MPX in the United States (US). Studies conducted in Africa suggest that previous-generation smallpox vaccines can protect against MPX. Nevertheless, data on the real-world effectiveness of third-generation smallpox vaccines against MPX were lacking from before the current outbreak. However, preliminary studies from the US and Israel indicate a substantially high level of protection from vaccination against MPX.

About the study

In the present observational study, researchers assessed the effectiveness of a single MVA-BN vaccine dose against symptomatic MPX among GBMSM in England. They implemented a case coverage or screening method comparing vaccination rates among cases with those in the population. Weekly vaccination rates among GBMSM individuals and the estimate of the GBMSM denominator were used to determine coverage.

The authors estimated 89,240 GBMSM individuals were at a high risk of MPX in England. Vaccination sites reported daily vaccinations by dose and cohort. The vaccination status was classified as recent (vaccinated in the current/past week) or one full dose (vaccinated at least two weeks before with a single dose). Second vaccinations were not considered since only fewer individuals received the second dose.

The vaccination status of cases was determined via questionnaires sent to confirmed or probable cases. Cases with an index date of July 4, 2022, or later until October 3, 2022, were included. Cases vaccinated after the index date were included as non-vaccinated. Cases vaccinated before 2022 were deemed non-vaccinated. Those with information only on the vaccination year (2022) without a date were included in the sensitivity analysis.

Findings

Weekly vaccination coverage increased to 47% by early October 2022, with most of the doses administered by August 22, 2022. Overall, 1,102 MPX cases completed questionnaires. Fifty-two cases were excluded from the investigation since they were female or heterosexual males. Of the cases, 460 had an index date of July 4, 2022, or later. Ninety-seven cases lacked an exact date of vaccination and were excluded; thus, 363 cases were considered for analysis.

Among these, eight cases were vaccinated more than two weeks before rash onset, 32 were vaccinated in less than two weeks, and the remaining were non-vaccinated, including those vaccinated many years before 2022. None of the cases reported second vaccination. The return rate of questionnaires was 33%.

The effectiveness of a single smallpox vaccine dose was 78%. In the sensitivity analyses, reducing the GBMSM denominator by 20%, which increased population vaccination coverage, resulted in a higher VE of 85%. Likewise, increasing the GBMSM denominator by 20% reduced effectiveness to 71%. Vaccine effectiveness was -4% within two weeks of receiving the single dose. When considering cases aged 50 or lower, the effectiveness was 74%.

Conclusions

The researchers estimated the effectiveness of one dose of the MVA-BN vaccine against symptomatic MPX to be 78% after a minimum of two weeks post-vaccination. There was no evidence of protection against disease in the 13 days post-vaccination. These estimates were concordant with the Israeli study, which found 79% efficacy of single-dose MVA-BN vaccine in GBMSM individuals.

The study’s limitations include the assumption that all cases were GBMSM unless they identified explicitly as heterosexual or female. Further, the researchers used questionnaire data for vaccination status since a national vaccination registry was unavailable. Moreover, people vaccinated pre-2022 were considered non-vaccinated, and if prior vaccination conferred protection to some degree, these estimates might have been lower than the actual effectiveness.

To summarize, the findings indicated that a single dose of the MVA-BN offered a relatively high level of protection against MPX. This suggested that when at-risk individuals exceed the vaccine supply for the two-dose regimen, prioritizing the administration of a single dose may be beneficial. Furthermore, future investigations are warranted to examine the durability of protection and effectiveness after two doses.

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

Journal references:

Article Revisions

  • May 17 2023 - The preprint preliminary research paper that this article was based upon was accepted for publication in a peer-reviewed Scientific Journal. This article was edited accordingly to include a link to the final peer-reviewed paper, now shown in the sources section.
Tarun Sai Lomte

Written by

Tarun Sai Lomte

Tarun is a writer based in Hyderabad, India. He has a Master’s degree in Biotechnology from the University of Hyderabad and is enthusiastic about scientific research. He enjoys reading research papers and literature reviews and is passionate about writing.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Sai Lomte, Tarun. (2023, May 17). Single-dose smallpox vaccine could be effective against mpox. News-Medical. Retrieved on December 05, 2024 from https://www.news-medical.net/news/20221219/Single-dose-smallpox-vaccine-could-be-effective-against-mpox.aspx.

  • MLA

    Sai Lomte, Tarun. "Single-dose smallpox vaccine could be effective against mpox". News-Medical. 05 December 2024. <https://www.news-medical.net/news/20221219/Single-dose-smallpox-vaccine-could-be-effective-against-mpox.aspx>.

  • Chicago

    Sai Lomte, Tarun. "Single-dose smallpox vaccine could be effective against mpox". News-Medical. https://www.news-medical.net/news/20221219/Single-dose-smallpox-vaccine-could-be-effective-against-mpox.aspx. (accessed December 05, 2024).

  • Harvard

    Sai Lomte, Tarun. 2023. Single-dose smallpox vaccine could be effective against mpox. News-Medical, viewed 05 December 2024, https://www.news-medical.net/news/20221219/Single-dose-smallpox-vaccine-could-be-effective-against-mpox.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Cleveland Clinic presents new findings on triple-negative breast cancer vaccine